Functional MRI paradigm to aid CNS drug development
Boston, MA, March 16, 2015 -- WorldCare Clinical (WCC), a leading provider of imaging services to the pharmaceutical and biotechnology industry, today announced that it has initiated collaboration with Massachusetts General Hospital (MGH) and the East West Integrative Medical Hospital and Research
Institute (EWIMHRI) to develop and scale the MRI paradigm necessary to map
brain functions during auditory and visual challenges.
and psychiatric diseases alter cognition. Sponsors are looking for sensitive
markers of changes in brain function to determine efficacy of many CNS
drugs," stated Dr. Richard Walovitch, President of WCC. "To our knowledge
we are the first imaging service provider to undertake this research
challenge. We feel confident that
combining the experience of the MGH clinical research team with our unique
understanding of imaging paradigms will operationalize this paradigm for use in
multi-center clinical trials."
About WorldCare Clinical
WorldCare Clinical is a global imaging CRO that
employs scientific expertise, innovative technology, and operational excellence
to maximize the precision and accuracy of a blinded independent central review
of Phase I – IV clinical trial data. The company has worked with thousands of
sites in more than 60 countries. WCC's robust technology platform processes
over 250 million images annually (CT, MRI, X-Ray, Echo, US, PET). Originally
founded in 1992 by the Massachusetts General Hospital (MGH) Department of
Radiology, WorldCare continues to maintain a strategic relationship with the
Harvard Hospital System as well as other leading academic institutions.
For more information on WCC's services, please visit
our website at www.wcclinical.com